Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
110.36
+1.18 (1.08%)
At close: Jul 2, 2024, 4:00 PM
109.00
-1.36 (-1.23%)
After-hours: Jul 2, 2024, 4:56 PM EDT
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $282.21M in the twelve months ending March 31, 2024, with 37.94% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $96.12M with 51.87% year-over-year growth. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.
Revenue (ttm)
$282.21M
Revenue Growth
+37.94%
P/S Ratio
24.49
Revenue / Employee
$430,853
Employees
655
Market Cap
6.91B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | 66.51M | 21.99M | 49.39% |
Dec 31, 2018 | 44.52M | 23.10M | 107.79% |
Dec 31, 2017 | 21.43M | -6.35M | -22.85% |
Dec 31, 2016 | 27.77M | 16.37M | 143.61% |
Dec 31, 2015 | 11.40M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elanco Animal Health | 4.37B |
The Ensign Group | 3.85B |
Jazz Pharmaceuticals | 3.84B |
Masimo | 1.98B |
Exelixis | 1.85B |
Penumbra | 1.10B |
Halozyme Therapeutics | 862.99M |
Ionis Pharmaceuticals | 776.62M |
BPMC News
- 12 hours ago - The Schall Law Firm Is Currently Probing Potential Securities Law Breaches For Shareholders Of Blueprint Medicines Corporation - Accesswire
- 1 day ago - At The Moment The Schall Law Firm Is Scrutinizing Possible Securities Law Violations For Investors of Blueprint Medicines Corporation - Accesswire
- 2 days ago - Now The Schall Law Firm Is Looking Into Potential Breaches Of Securities Laws For Stockholders Of Blueprint Medicines Corporation - Accesswire
- 3 days ago - At This Time The Schall Law Firm Is Examining Potential Infringements Of Securities Laws For Equity Holders Of Blueprint Medicines Corporation - Accesswire
- 4 days ago - Currently The Schall Law Firm Is Investigating Possible Securities Law Breaches For Shareholders Of Blueprint Medicines Corporation - Accesswire
- 5 days ago - Currently The Schall Law Firm Is Investigating Possible Violations Of Securities Laws For Shareholders Of Blueprint Medicines Corporation - Accesswire
- 6 days ago - At Present The Schall Law Firm Is Probing Potential Securities Law Violations For Stock Owners Of Blueprint Medicines Corporation - Accesswire
- 7 days ago - The Schall Law Firm Is At Present Investigating Possible Breaches Of Securities Laws For Shareholders Of Blueprint Medicines Corporation - Accesswire